BioSpace News Archive

The U.S. Food and Drug Administration (FDA), a day after a positive advisory committee recommendation, granted an Emergency Use Authorization (EUA) to Pfizer and BioNTech for their COVID-19 vaccine. Dosing is expected to begin in days.

Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash,

Aptorum Group Limited, a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced the results of its 2020 annual general meeting of shareholders, which was held on December 9, 2020, in Hong Kong.

Instem Launches In Silico Toxicology Service Technology-enabled service delivers fast, efficient, comprehensive in silico toxicology predictions

Gilead Sciences Canada, Inc. (Gilead Canada) announced today that YESCARTA® (axicabtagene ciloleucel) is now available in Ontario as a treatment for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma

CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced the closing of a $47 million Series D preferred stock financing led by new investor Kissei Pharmaceutical Co., Ltd., with participation from existing investors ORI Healthcare Fund, Camford Capital and Perseverance Capital Management.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the selection of three abstracts for presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually on January 15 – 17, 2021.

Jaguar to Host Investor Call Thursday, December 17th at 8:30 a.m. Eastern to Allow Management to Review Developments that Have Taken Place Since the Definitive Proxy Statement was Filed As previously announced, Nasdaqs Listing and Hearing Review Council Stayed the Panel Determination Requiring Jaguars Compliance with the Bid Price Requirement by December 23, 2020

AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib (30 mg, once daily) achieved superiority to dupilumab (300 mg, every other week) for the primary endpoint, the proportion of patients with at least a 75 percent improvement in the Eczema Area Severity Index (EASI 75) at week 16, in adults with moderate to severe atopic dermatitis

THREAD, an innovative technology and service provider that enables decentralized clinical research, joins a formidable alliance of 50 life sciences and healthcare organizations to accelerate the broad adoption of patient-focused decentralized clinical trials and research.